Holen Sie sich die Stockscreener-App
24.39
1.81%
-0.45
Handel nachbörslich:
24.40
0.010
+0.04%
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BioAge advances inflammaging drug into Phase 2 - Longevity.Technology
Price to sales forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Enterprise value to EBITDA forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Frau - GuruFocus
Bioage Labs stock hits 52-week high at 25.8 USD - Investing.com
Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102 - Sahm
Form 4 Bioage Labs Inc For: 1 July By Investing.com - Investing.com Nigeria
BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: - GuruFocus
Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing - Moomoo
BioAge Labs principal accounting officer sells $1.57m in stock - Investing.com
BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com - Investing.com South Africa
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs (BIOA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Biotech Development StageMid-Term Outlook - dars.gov.et
BIOA (NASDAQ: BIOA) Form 144 filed for 42,350-share proposed sale - Stock Titan
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? - Yahoo Finance
Form 144 BioAge Labs For: 29 June By Investing.com - Investing.com Nigeria
BIOA (BIOA) Form 144 lists proposed sales of 2,632 and 39,718 shares - Stock Titan
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2000 Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 3000E Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 3000 Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Enterprise value to EBIT forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
BioAge Labs (BIOA) Tests BGE-102 in Phase 2 Trial, But What Does It Signal Strategically? - Sahm
BioAge Labs, Inc. Actuals & Estimates (NASDAQ:BIOA) - TradingView
BIOAGE Labs Inc (BIOA) Institutional Confidence - TradingKey
BioAge Labs, Inc. Actuals & Estimates (GETTEX:Y7G) - TradingView
Enterprise value to EBITDA forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
Bioage Labs stock hits 52-week high at 24.03 USD By Investing.com - Investing.com Australia
Bioage Labs stock hits 52-week high at 24.03 USD - Investing.com UK
Enterprise value to revenue forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
Price to earnings forward of BioAge Labs, Inc. – GETTEX:Y7G - TradingView
BIOA Forecast — Price Target — Prediction for 2027 - TradingView
BioAge Labs (BIOA) Is Up 14.2% After Starting Phase 2 Trial Of Oral NLRP3 Inhibitor - Yahoo Finance
BioAge Labs: Developing A 'Pipeline In A Pill' (NASDAQ:BIOA) - Seeking Alpha
BIOAGE Labs Inc (BIOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
BIOA News | BIOAGE LABS INC (NASDAQ:BIOA) - ChartMill
BIOAGE Labs Inc (BIOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Pend - GuruFocus
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Hold Rating, Maintains Target Price $23 - Moomoo
BIOAGE Labs Inc (BIOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BIOAGE Labs Inc (BIOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BIOAGE Labs Inc (BIOA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIOAGE Labs Inc (BIOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioAge doses first patient in phase 2 cardiovascular trial - Investing.com
BioAge doses first patient in phase 2 cardiovascular trial By Investing.com - Investing.com South Africa
BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102 for Cardiovascular Risk - marketscreener.com
A daily pill to calm heart inflammation? BioAge tests BGE-102 - Stock Titan
BioAge Labs Announces First Participant Dosed in QUELL-CV, - GlobeNewswire
0.15%
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):